Hospital Universitario Fundacion Jimenez Diaz
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, heart disorder, heart failure, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05374291 | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | Chronic Migraine | Active, not recruiting | Phase 3 | 2026-09-04 | NCT06047444 | |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-09-03 | NCT05673187 | |
| Controlling Hyperactive Immunity With Long-lived Lymphocytes | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, skin disorder, systemic sclerosis | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT07473154 | |
| An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-31 | NCT05876754 | |
| Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 1 | 2026-07-30 | NCT05464030 | |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-06 | NCT05948475 | |
| A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD | acute graft versus host disease, graft versus host disease, immune system disorder | Active, not recruiting | Phase 2 | 2026-05-26 | NCT05643638 | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-05-22 | NCT04628494 | |
| Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-03-18 | NCT06726265 | |
| A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, focal segmental glomerulosclerosis, glomerulonephritis, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-02-03 | NCT05183646 | |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-29 | NCT03974022 | |
| Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric cancer, gastric neoplasm, head and neck squamous cell carcinoma, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-01-28 | NCT07151040 | |
| Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | cancer, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-28 | NCT06840119 | |
| First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | Solid Tumor, Adult | Recruiting | Phase 1 / Phase 2 | 2024-11-07 | NCT06622486 |